biostudies-literatureUnknown10(12)About F<h4>Background</h4>Human genetic factors influence the outcome of pegylated interferon and ribavirin hepatitis C therapy. We explored the role of IL28B, APOH and ITPA SNPs on the outcomes of triple therapy including telaprevir or boceprevir in patients with compensated cirrhosis chronically infected with HCV-1.<h4>Patients and methods</h4>A total of 256 HCV-1 Caucasian treatment-experienced patients with compensated cirrhosis from the ANRS CO20-CUPIC cohort were genotyped for a total of 10 candidate SNPs in IL28B (rs12979860 and rs368234815), APOH (rs8178822, rs12944940, rs10048158, rs52797880, rs1801689 and rs1801690) and ITPA (rs1127354 and rs7270101). We tested the association of IL28B and APOH SNPs with sustained virological response and of ITPA SNPs with anemia related phenotypes by mPloS onee0145105https://www.ebi.ac.uk/biostudies/studies/S-EPMC4682920biostudies-literatureImpact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study.PMC4682920Denis JOudot-Mellakh TDi-Martino VHillon PCacoub PFeray CArpurt JPBotta-Friedland DZahraa NTheodorou IDe Ledinghen VDuffy DLucidarme DRabiega PPoncin EPawlotsky JMAttali PBernard PHRiachi GCagnot CPetrov-Sanchez VRenard PChazouilleres OFontaine HMetivier SBacq YSultanik PAbel LDubuisson Jde Montigny-Lenhardt SDelasalle PAllegre TZoulim FNiay JPedergnana VCombis JMBarthe YTrinchet JCLesel AParadis VZarski JPPol SLascoux-Combe CSerfaty LGrange JDPageaux GPPoynard TAbergel ADao TAbout FDufour CPirot MHezode CGrando-Lemaire VCobat AMarcellin PCanva VOuzan DBedossa PSpire BFrehaut CChau FSizorn MCales PTran APilette CRosa ITaburet AMYazdanpanah YANRS CO20-CUPIC study groupLoustaud-Ratti VCarrat FFontanges TBronowicki JPGuyader DDorival-Mouly CBourliere MGatineau-Sailliant GFranck GNegro FAlric LL'Henaff MLarrey DAlbert MLRibard DCausse XSylvain CSchnee MRaabe JJNousbaum JBSamuel DfalseImpact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study.<h4>Background</h4>Human genetic factors influence the outcome of pegylated interferon and ribavirin hepatitis C therapy. We explored the role of IL28B, APOH and ITPA SNPs on the outcomes of triple therapy including telaprevir or boceprevir in patients with compensated cirrhosis chronically infected with HCV-1.<h4>Patients and methods</h4>A total of 256 HCV-1 Caucasian treatment-experienced patients with compensated cirrhosis from the ANRS CO20-CUPIC cohort were genotyped for a total of 10 candidate SNPs in IL28B (rs12979860 and rs368234815), APOH (rs8178822, rs12944940, rs10048158, rs52797880, rs1801689 and rs1801690) and ITPA (rs1127354 and rs7270101). We tested the association of IL28B and APOH SNPs with sustained virological response and of ITPA SNPs with anemia related phenotypes by m2015-01-01T00:00:00Z20152026-05-05T08:07:18.512Z2026-04-07T21:31:29.849ZS-EPMC46829202667010010.1371/journal.pone.0145105